TRAIL, Bim, and Thymic-Negative Selection

Immunologic Research

Volumn 28, Issue 3, 2003, Pages 295-301

  Zheng, Shi Jun ^a   Chen, Youhai H ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; Bim; Central tolerance; T cell development; TRAIL

Indexed keywords

APOPTOSIS INDUCING FACTOR; BIM PROTEIN; CASPASE 8; CYTOKINE RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; MONOCLONAL ANTIBODY CD3; OVALBUMIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOIMMUNITY; CELL MATURATION; COCULTURE; CYTOKINE RELEASE; ENZYME ACTIVATION; HORMONE RELEASE; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THYMOCYTE; UPREGULATION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; MODELS, IMMUNOLOGICAL; PROTO-ONCOGENE PROTEINS; SELF TOLERANCE; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0347126456     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:28:3:295     Document Type: Review

References (52)

1. Goldsby RA, Kindt TJ, Osborne BA: Kuby Immunology (4th ed). W.H. Freeman and Company, 2000.
2. Sprent J, Webb SR: Intrathymic and extrathymic clonal deletion of T cells. Current Opin Immunol 1995;7: 196-205.
3. Sprent J, Kishimoto H: The thymus and negative selection. Immunol Rev 2002;185:126-135.
4. Kishimoto H, Sprent J: The thymus and central tolerance. Clin Immunol 2000;95:S3-S7.
5. Page DM, Roberts EM, Peschon JJ, Hedrick SM: TNF receptor-deficient mice reveal striking differences between several models of thymocyte negative selection. J Immunol 1998;160:120-133.
6. Muller KP, Mariani, SM, Matiba B, Kyewski B, Krammer PH: Clonal deletion of major histocompatibility complex class I-restricted CD4+CD8+ thymocytes in vitro is independent of the CD95 (APO-1/Fas) ligand. Eur J Immunol 1995;25:2996-2999.
7. Adachi M, Suematsu S, Suda T, Watanabe D, Fukuyama H, Ogasawara J, et al.: Enhanced and accelerated lymphoproliferation in Fas-null mice. Proc Natl Acad Sci USA 1996;93:2131-2136.
8. Kishimoto H, Surh CD, Sprent J: A role for Fas in negative selection of thymocytes in vivo. J Exp Med 1998; 187;1427-1438.
9. Yui K, Wadsworth S, Yellen A, et al.: Molecular and functional properties of novel T cell subsets in C3H-gld/gld and nude mice. Implications for thymic and extrathymic maturation. Immunol Rev 1988;104: 121-155.
10. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, Peschon J, Chen YH: Defective Thymocyte Apoptosis and Accelerated Autoimmune Diseases in TRAIL-null Mice. Nature Immunol 2003;4(3):255-260.
11. Bouillet P, Purton JF, Godfrey DI, Zhang LC, Coultas L, Puthalakath H, et al.: BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 2002;415:922-926.
12. Singer GG, Abbas AK: The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994;1:365-371.
13. Wiley SR, Schooley K, Smolak PJ, et al.: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682.
14. Pan, G, Ni J, Wei YF, et al.: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-818.
15. Pan G, Ni J, Yu G, Wei YF, Dixit VM: TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Letters 1998;424:41-45.
16. Schneider P, Bodmer JL, Thome M, et al.: Characterization of two receptors for TRAIL. FEBS Letters 1997; 416:329-334.
17. Sheikh MS, Burns TF, Huang Y, et al.: p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998;58:1593-1598.
18. Sheridan JR Marsters SA, Pitti RM, et al.: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-821.
19. Walczak H, Degli-Esposti MA, Johnson RS, et al.: TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-5397.
20. Screaton GR, Mongkolsapaya J, Xu XN, et al.: TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Current Biol 1997; 7:693-696.
21. Sprick MR, Weigand MA, Rieser E, et al.: FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12: 599-609.
22. Bodmer JL, Holler N, Reynard S, et al.: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000;2:241-243.
23. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P: Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 2001;61:7339-7348.
24. Deng Y, Lin Y, Wu X: TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/ DIABLO. Genes Dev 2002;16:33-45.
25. Abulencia JP, Gaspard R, Quackenbush J, konstantopoulos K: Discovery and characterization of differentially regulated genes in the chondrocytic cell line T/C-28a2 under dynamic fluid shear. FASEB J 2002; 16:A656.657.
26. Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS: Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 1999;59:2770-2775.
27. Mariani SM, Krammer PH: Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur J Immunol 1998;28:1492-1498.
28. Jeremias I, Herr I, Boehler T, Debatin KM: TRAIL/ Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol 1998;28:143-152.
29. Walczak H, Miller RE, Ariail K, et al.: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med 1999;5:157-163.
30. Ashkenazi A, Pai RC, Fong S, et al.: Safety and antitumor activity of recombinant soluble Apo2 ligand. Journal of Clinical Invest 1999;104:155-162.
31. Jo M, Kim TH, Seol DW, et al.: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6:564-567.
32. Simon AK, Williams O, Mongkolsapaya J, et al.: Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes. Proc Natl Acad Sci USA 2001;98:5158-5163.
33. Martin-Villalba A, Herr I, Jeremias I, et al.: CD95 ligand (Fas-L/APO-IL) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci 1999;19: 3809-3817.
34. Ursini-Siegel J, Zhang W, Altmeyer A, Hatada EN, Do RKG, Yagita H, et al.: TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J Immunol 2002;169: 5505-5513.
35. Woodland DL, Happ MP, Gollob KJ, Palmer E: An endogenous retrovirus mediating deletion of alpha beta T cells? Nature 1991;349:529-530.
36. Tomonari K, Fairchild S, Rosenwasser OA: Influence of viral superantigens on V beta-and V alpha-specific positive and negative selection. Immunol Rev 1993; 131:131-168.
37. O'Connor L, Strasser A, O Reilly LA, Hausmann G, Adams JM, Cory S, et al.: Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO 1998; 17(2):384-395.
38. Marani M, Tenev T, Hancock D, Downward J, Lemoine NR: Identification of novel isoforms of the BH3 Domain protein Bim which directly activate Bax to trigger apoptosis. Mol Cell Biol 2002;22(11):3577-3589.
39. Bouillet P, Metcalf D, Huang DCS, Tarlinton DM, Kay TWH, Kontgen F, et al.: Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999;286:1735-1738.
40. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB: BH3-only proteins that bind prosurvival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001;15: 1481-1486.
41. L sequester BH3 domain-only molecules preventing Bax-and Bak-mediated mitochondrial apoptosis. Mol Cell 2001;8:705-711.
42. Castro JE, Listman JA, Jacobson BA, et al.: Fas modulation of apoptosis during negative selection of thymocytes. Immunity 1996;5:617-627.
43. Sytwu HK, Liblau RS, McDevitt HO: The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 1996;5:17-30.
44. Zhang J, Cado D, Chen A, Kabra NH, Winoto A: Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mortl. Nature 1998;392:296-300.
45. Kuida K, Haydar TF, Kuan CY, et al.: Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998;94:325-337.
46. Walsh CM, Wen BG, Chinnaiyan Am, et al.: A role for FADD in T cell activation and development. Immunity 1998;8:439-449.
47. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ: bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991;67:879-888.
48. Chaudhary PM, Eby M, Jasmin A, et al.: Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosiis and activate the NF-kappaB pathway. Immunity 1997;7:821-830.
49. Schneider P, Thome M, Burns K, et al.: TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997;7: 831-836.
50. Hu WH, Johnson H, Shu HB: Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways. J Biol Chem 1999;274: 30603-30610.
51. Lin Y, Devin A, Cook A, et al.: The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 2000;20;6638-6645.
52. Kumar-Sinha C, Varambally S, Sreekumar A, Chinnaiyan AM: Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem 2002; 277:575-585.